MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -415.60K | 284.90K | 128.70K |
| Total Revenue | -- | -- | -415.60K | 284.90K | 128.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -415.60K | 284.90K | 128.70K |
| SG&A Expenses | 76.80K | 29.10K | 96.70K | 138.30K | 80.60K |
| Depreciation & Amortization | 57.80K | -- | -58.40K | 26.50K | 31.50K |
| Other Operating Expenses | -- | 17.80K | -- | -- | -- |
| Total Operating Expenses | 134.60K | 46.90K | 38.30K | 164.70K | 112.10K |
| Operating Income | -134.60K | -46.90K | -453.90K | 120.20K | 16.60K |
| Income Before Tax | -250.00K | -30.30K | -174.30K | 50.50K | -26.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -250.00K | -30.30K | -174.30K | 50.50K | -26.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.80K | -400.00 | -- | -- | -- |
| Net Income | -247.20K | -30.70K | -174.30K | 50.50K | -26.10K |
| EBIT | -134.60K | -46.90K | -453.90K | 120.20K | 16.60K |
| EBITDA | -105.70K | -- | -- | 146.60K | 48.10K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 135.17M | 133.99M | 137.01M | 131.73M | 100.19M |
| Average Diluted Shares Outstanding | 135.17M | 133.99M | 137.01M | 131.73M | 100.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
